Indian generics giant Dr Reddy’s Laboratories announced on 12 August 2015 that it had launched generic pramipexole dihydrochloride extended-release tablets in dosages of 0.375, 0.75, 1.5, 3 and 4.5 mg, following approval of the company’s abbreviated new drug application by the US Food and Drug Administration on 7 August 2015.
Generic Parkinson’s drug hits US market
Generics/News
|
Posted 21/08/2015
0
Post your comment
The drug is a generic version of Boehringer Ingelheim’s Parkinson’s treatment Mirapex ER (pramipexole). US sales of brand-name and generic pramipexole were approximately US$48.3 million for the last 12 months ending June 2015, according to IMS Health.
Boehringer Ingelheim only received approval for its Parkinson’s drug in 2010 and had expected patents to protect it until 2028 and 2029. However, there are now numerous generics makers with pramipexole generics on the market in the US.
Related article
Generics will grab Parkinson’s disease market share
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.
Source: Dr Reddy’s, US FDA
Research
Japan’s drug shortage crisis: challenges and policy solutions
Saudi FDA drug approvals and GMP inspections: trend analysis
Related content
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment